DNA sequence-selective adenine alkylation, mechanism of adduct repair, and in vivo antitumor activity of the novel achiral seco-amino-cyclopropylbenz[e] indolone analogue of duocarmycin AS-I-145

Molecular Cancer Therapeutics

Volumn 6, Issue 10, 2007, Pages 2708-2718

  Kiakos, Konstantinos ^a   Sato, Atsushi ^b   Asao, Tetsuji ^b   McHugh, Peter J ^a,d   Lee, Moses ^c   Hartley, John A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c HOPE COLLEGE   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AS I 145; DUOCARMYCIN DERIVATIVE; PLASMID DNA; RACHELMYCIN; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DNA REPAIR; DNA SEQUENCE; EXCISION; EXCISION REPAIR; HEALTH CARE ORGANIZATION; HOLLOW FIBER; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; TRANSCRIPTION INITIATION; XENOGRAFT; YEAST; YEAST CELL;

ADENINE; ALKYLATING AGENTS; ALKYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; DRUG EVALUATION, PRECLINICAL; HUMANS; INDOLES; MICE; MOLECULAR STRUCTURE; PYRROLES; SACCHAROMYCES CEREVISIAE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35848960151     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0294     Document Type: Article

References (70)

1. Li LH, Swenson DH, Schpok SLF, Kuentzel BD, Dayton BD, Krueger WC. CC-1065 (NSC 298223), a novel antitumour agent that interacts strongly with double-stranded DNA. Cancer Res 1982;42:999-1004.
2. Boger DL. Design, synthesis, and evaluation of DNA minor groove bindingag ents: the duocarmycins. Pure Appl Chem 1994;66:837-44.
3. Hanka LJ, Dietz A, Gerpheide SA, Kuentzel SL, Martin DG. CC-1065 (NSC-298223), a new antitumour antibiotic. Production, in-vitro biological activity, microbiological assays, and taxonomy of the producing microorganism. J Antibiot (Tokyo) 1978;31:1211-7.
4. Ichimura M, Ogawa T, Takahashi K, et al. Duocarmycin SA, a new antitumor antibiotic from Streptomyces sp. J Antibiot (Tokyo) 1990;43:1037-8.
5. Needham-VanDevanter DR, Hurley LH, Reynolds VL, Theriault NY, Krueger WC. Wierenga W. Characterisation of an adduct between CC-1065 and a defined oligodeoxynucleotide duplex. Nucleic Acids Res 1984;12:6159-68.
6. Reynolds VL, Molineaux IJ, Kaplan DJ, Swenson DH, Hurley LH. Reaction of the antitumour antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity. Biochemistry 1985;24:6228-37.
7. Boger DL, Johnson DS, Yun W. (+)- and ent-(-)-Duocarmycin SA and (+)- and ent-(-)-N-BOC-DSA DNA alkylation properties. Alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity of the enantiomeric agents. J Am Chem Soc 1994;116:1635-56.
8. Hurley LH, Reynolds VL, Swenson DH, Petzold GL, Scahill TA. Reaction of the antitumour antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science 1984;226:843-4.
9. Boger DL, Yun W. Reversibility of the duocarmycin A, SA DNA alkylation reaction. J Am Chem Soc 1993;115:9872-3.
10. Igarashi Y, Futamata K, Fujita T, et al. Yatakemycin, a novel antifungal antibiotic produced by Streptomyces sp. TP-A0356. J Antibiot (Tokyo) 2003;56:107-13.
11. Parrish JP, Kastrinsky DB, Wolkenberg SE, Igarashi Y, Boger DL. DNA alkylation properties of yatakemycin. J Am Chem Soc 2003;125:10971-6.
12. McGovern JP, Clarke GL, Pratt EA, Dekoning TF. Preliminary toxicity studies with the DNA binding antibiotic CC-1065, a potent antitumour antibiotic. J Antibiot (Tokyo) 1984;37:63-70.
13. Boger DL, Johnson DS. CC-1065 and the duocarmycins: understanding their biological function through mechanistic studies. Angew Chem Int Ed Engl 1996;35:1438-74.
14. Amishiro N, Okamoto A, Murakata C, Tamaoki T, Okabe M, Saito H. Synthesis and antitumor activity of duocarmycin derivatives: modification of segment-A of A-ring pyrrole compounds. J Med Chem 1999;42:2946-60.
15. Weiland KL, Dooley TP. In vitro and in vivo bondingby the CC-1065 analogue U-73975. Biochemistry 1991;30:7559-65.
16. Li LH, DeKoning TF, Kelly RC, et al. Cytotoxicity and antitumor activity of carzelesin, a prodrugcyclopro pylpyrroloindole analogue. Cancer Res 1992;52:4904.
17. Walker DL, Reid JM, Ames MM. Preclinical pharmacology of bizelesin, a potent bifunctional analogof the DNA-binding antibiotic CC-1065. Cancer Chemother Pharmacol 1994;34:317-22.
18. Nagamura S, Kobayashi E, Comi K, Saito H. Studies on the active metabolite (DU-86) of KW-2189, a novel derivative of duocarmycin. Bioorg Med Chem Lett 1996;6:2147-50.
19. Shamdas GJ, Alberts DS, Modiano M, et al. Phase I study of adozelesin (U-73,975) in patients with solid tumours. Anticancer Drugs 1994;5:10-4.
20. Pavlidis N, Aamdal S, Awada A, et al. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). Cancer Chemother Pharmacol 2000;46:167-71.
21. Pitot HC, Reid JM, Sloan JA et al. A phase I study of bizelesin (NSC 615291) in patients with advanced solid tumours. Clin Cancer Res 2002;8:712-7.
22. Alberts SR, Erlichman C, Reid JM, et al. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin. Cancer Res 1998;4:2111-7.
23. Howard TT, Lingerfelt BM, Purnell BL, et al. Novel furano analogs of duocarmycin C1 and C2: design, synthesis and biological evaluation of seco-iso-cyclopropylfurano[2,3-e]indoline (seco-iso-CFI) and seco-cyclopropyltetrahydrofurano[2,3-f]quinoline (seco-CFQ) analogues. Bioorg Med Chem 2002;10:2941-52.
24. Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 2002;1:753-68.
25. Kupchinsky S, Centioni S, Howard T, et al. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties. Bioorg Med Chem 2004;12:6221-36.
26. Toth JL, Trzupek JD, Flores LV, et al. A novel achiral seco-amino-cyclopropylindoline (CI) analogof CC-1065 and the duocarmycins: design, synthesis and biological studies. Med Chem 2005;1:13-9.
27. 2: CC-1065 functional agents incorporating the equivalent 1,2,9,9a-tetrahydrocycloprop[1,2- c]benz[1,2-e]indol-4-one (CBI) left-hand subunit. J Am Chem Soc 1989;11:6461-3.
28. 2: enhanced functional analogs of (+)-CC-1065. A critical appraisal of a proposed relationship between electrophile reactivity, DNA binding properties, and cytotoxic potency. Tetrahedron Lett 1990;31:793-6.
29. Boger DL, Yun W, Teergarden BR. An improved synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI): a simplified analogue of the CC-1065 alkylation subunit. J Org Chem 1992;57:2873-6.
30. Boger DL, Yun W, Han N. 1,2,9,9a-Tetrahydrocyclopropa[c] bennz[e]indol-4-one (CBI) analogs of CC-1065 and the duocarmycins: synthesis and evaluation. BioorgMed Chem 1995;3:1429-53.
31. Sato A, McNulty L, Cox K et al. A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065. J Med Chem 2005;48:3903-18.
32. Brooks N, McHugh PJ, Lee M, Hartley JA. Alteration in the choice of DNA repair pathway with increasingsequ ence selective DNA alkylation in the minor groove. Chem Biol 2000;7:659-68.
33. Clingen PH, De Silva IU, McHugh PJ, et al. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4] benzodiazepine dimer SJG-136. Nucleic Acids Res 2005;33:3283-91.
34. Wyatt MD, Lee M, Garbiras B, Souhami RL, Hartley JA. Sequence specificity of alkylation for a series of nitrogen mustard- containing analogues of distamycin of increasing binding site size: evidence for increased cytotoxicity with enhanced sequence specificity. Biochemistry 1995;34:13034-41.
35. Ponti M, Forrow SM, Souhami RL, D'Incalci M, Hartley JA. Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase. Nucleic Acids Res 1991;19:2929-33.
36. Hartley JA, Wyatt MD. Determination of the DNA sequence specificity of alkylation damage using cleavage-based assays. In: Fox KR editor. Methods in molecular biology, Vol. 90: Drug DNA interaction protocols. Totowa (NJ): Humana Press Inc.; 1997. p. 147-56.
37. Xiao W, Chow BL, Rathgeber L. The repair of DNA methylation damage in Saccharomyces cerevisiae. Curr Genet 1996;30:461-8.
38. Wach A, Brachat A, Pohlmann R, Philippsen P. New heterologous modules for classical or PCR-based gene disruptions in Saccharomyces cerevisiae. Yeast 1994;10:1793-808.
39. Kiakos K, Howard TT, Lee ML, Hartley JA, McHugh PJ. Saccharomyces cerevisiae RAD5 influences the excision repair of DNA minor groove adducts. J Biol Chem 2002;277:44576-81.
40. Chen J, Derfler, Samson L. Saccharomyces cerevisiae 3-methyladenine DNA glycosylase has homology to the AlkA glycosylase of E. coli and is induced in response to DNA alkylation damage. EMBO J 1990;9:4569-75.
41. Grimaldi KA, McAdam SR, Souhami RL, Hartley JA. DNA damage by anti-cancer agents resolved at the nucleotide level of a single copy gene: evidence for a novel bindingsite for cisplatin in cells. Nucleic Acids Res 1994;22:2311-7.
42. Grimaldi KA, Hartley JA. PCR-based methods for detecting DNA damage and its repair at the subgene and single nucleotide levels in cells. In: Fox KR editor. Methods in molecular biology, Vol. 90: Drug-DNA interactions protocols. Totowa (NJ): Humana Press Inc.; 1997. p. 157-80.
43. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
44. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cel Biol 2000;20:7980-90.
45. Hollingshead MG, Alley MC, Camalier RF, et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci 1995;57:131-41.
46. Daniell K, Stewart M, Madsen E, et al. Design, synthesis, and biological evaluation of achiral analogs of duocarmycin SA. Bioorg Med Chem Lett 2005;15:177-80.
47. Boger DL, Yun W. CBI-TMI: synthesis and evaluation of a key analog of the duocarmycins. Validation of a direct relationship between chemical solvolytic stability and cytotoxic potency and confirmation of the structural features responsible for the distinguishing behaviour of enantiomeric pairs of agents. J Am Chem Soc 1994;116:7996-8006.
48. Trzupek JD, Gottesfeld JM, Boger DL. Alkylation of duplex DNA in nucleosome core particles by duocarmycin SA and yatakemycin. Nat Chem Biol 2006;2:79-82.
49. 2: CC-1065 functional analogues incorporating the parent 1,2,7,7a-Tetrahydrocycloprop[1,2-c]indol-4-one (CI) left-hand subunit. J Org Chem 1989;54:1238-40.
50. Boger DL, Ishizaki T, Zarrinmayeh H. Synthesis and preliminary evaluation of agents incorporating the pharmacophore of the duocarmycin/pyrindamycin alkylation subunit: identification of the CC-1065/duocarmycin common pharmacophore. J Org Chem 1990;55:4499-502.
51. Boger DL, Ishizaki T, Zarrinmayeh H, Munk SA, Kitos PA, Suntornwat O. Duocarmycin-pyrindamycin DNA alkylation properties and identification, synthesis, and evaluation of agents incorporating the pharmacophore of the duocarmycin-pyrindamycin alkylation subunit. Identification of the CC-1065-duocarmycin common pharmacophore. J Am Chem Soc 1990;112:8961-71.
52. Boger DL, McKie JA. An efficient synthesis of 1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI): an enhanced and simplified analog of CC-1065 and duocarmycin alkylation subunits. J Org Chem 1995;60:1271-5.
53. Woynarowski JM. Targeting regions in genomic DNA with AT-specific anticancer drugs. Biochim Biophys Acta 2002;1587:300-8.
54. Selby CP, Sancar A. ABC excinuclease incises both 5′ and 3′ to the CC-1065-DNA-adduct and its incision is stimulated by DNA helicase II and DNA polymerase I. Biochemistry 1998;27:7184-8.
55. Nazimiec M, Lee CS, TangYL, Ye X, Case R, Tang MS. Sequence-dependent interactions of the two forms of UvrC with DNA helix stabilising CC-10 65-N3-adenine adducts. Biochemistry 2001;40:11073-81.
56. Gunz D, Hess MT, Naegeli H. Recognition of DNA adducts by human nucleotide excision repair. J Biol Chem 1996;271:25089-98.
57. Imperatori L, Damia G, Taverna P, et al. 3T3 NIH murine fibroblasts and B78 murine melanoma cells expressingthe Escherichia coli N3-methyladenine-DNA-glycosylase I do not become resistant to alkylating agents. Carcinogenesis 1994;15:533-7.
58. 6-alkylguanine-DNA- alkyltransferase activities and sensitivity to alkylatingag ents in human cancer cell lines. Br J Cancer 1996;73:861-5.
59. Jin SG, Choi JH, Ahn B, O'Connor TR, Mar W, Lee CS. Excision repair of adozelesin-N3 adenine adduct by 3-methyladenine-DNA glycosylase and UvrABC nuclease. Mol Cells 2001;11:41-7.
60. Bailly V, Lamb J, Sung P, Prakash S, Prakash L. Specific complex formation between yeast RAD6 and RAD18 proteins: a potential mechanism for targeting RAD6 ubiquitin-conjugating activity to DNA damage sites. Genes Dev 1994;8:811-20.
61. Bailly V, Lauder S, Prakash S, Prakash L. Yeast DNA repair proteins Rad6 and Rad18 form a heterodimer that has ubiquitin conjugating, DNA binding, and ATP hydrolytic activities. J Biol Chem 1997;272:23360-5.
62. Broomfield S, Hryciw T, Xiao W. DNA postreplication repair and mutagenesis in Saccharomyces cerevisiae. Mutat Res 2001;486:167-84.
63. Joazeiro CA, Weissman AM. Ring finger proteins: mediators of ubiquitin ligase activity. Cell 2000;102:549-52.
64. Reynolds VL, McGovern JP, Hurley LH. The chemistry, mechanism of action and biological properties of CC-1065, a potent antitumor antibiotic. J Antibiot (Tokyo) 1986;39:319-34.
65. Damia G, Imperatori L, Stefanini M, D'Incalci M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 1996;66:779-83.
66. Tang MS, Qian M, Pao A. Formation and repair of antitumour antibiotic CC-1065-induced DNA adducts in the adenine phosphoribosyltransferase and amplified dihydrofolate reductase genes of Chinese hamster ovary cells. Biochemistry 1994;33:2726-32.
67. Jaspers NG, Raams A, Kelner MJ, et al. Anti-tumour compounds illudin S and irofulven induce DNA lesions ignored by global repair and exclusively processed by transciption- and replication-coupled repair pathways. DNA repair 2002;1:1027-38.
68. Koeppel F, Poindessous V, Lazar V, Raymond E, Sarasin A, Larsen AK. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumour cells. Clin Cancer Res 2004;10:5604-13.
69. Pommier Y, Kohlagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selective Alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumour compound from the Caribbean tunicate Ecteinascidia turbinara. Biochemistry 1996;35:13303-9.
70. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nature Med 2001;7:961-6.